Avalo Therapeutics Inc (AVTX)vsVertex Pharmaceuticals Inc (VRTX)
AVTX
Avalo Therapeutics Inc
$13.45
-0.37%
HEALTHCARE · Cap: $248.44M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 6250577% more annual revenue ($12.00B vs $192,000). VRTX leads profitability with a 32.9% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
AVTX
Avoid24
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVTX.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -1.7% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AVTX
The strongest argument for AVTX centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : AVTX
The primary concerns for AVTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
AVTX profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
AVTX carries more volatility with a beta of 0.89 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 24/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avalo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Avalo Therapeutics Inc is a pioneering clinical-stage biotechnology company focused on developing innovative therapies for rare and underserved conditions, particularly in the realm of immunological regulation. With a robust pipeline of proprietary candidates targeting serious diseases with significant unmet medical needs, Avalo leverages its deep expertise in disease mechanisms to advance its therapeutic programs through rigorous clinical trials. The company's dedication to scientific innovation and a patient-centric approach positions it to navigate the complexities of the biopharmaceutical industry effectively, with the goal of delivering transformative therapies to improve patient outcomes.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?